Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Pinealon
Beginner tier: 100 mcg, daily · 4w on / 8w off · community consensus
Also known as: EDR, Glu-Asp-Arg, Pinealon
Three amino acids. Glu-Asp-Arg. That is the entire sequence of Pinealon (EDR), a synthetic tripeptide bioregulator developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Fluorescence-labeled studies confirmed it reaches cell nuclei, where it interacts with DNA promoter regions tied to melatonin synthesis and neuroprotection. Formal human clinical trials? Zero. But community users running 10 to 20 day courses consistently describe improved sleep onset and circadian rhythm correction, particularly shift workers and adults over 40. The research base is narrow and originates from a single group; the community signal, while small, is directionally consistent.
What Is Pinealon?
Twenty-two papers on PubMed as of October 2026, nearly all from one laboratory. That is the evidence base behind Pinealon, also known as EDR (Glu-Asp-Arg, molecular weight 418.4 Da, CAS 175175-23-2). This synthetic tripeptide belongs to the Khavinson bioregulator family, short peptides designed to reach the nucleus and modulate gene expression in specific tissues.
The target tissue here is the pineal gland and broader central nervous system. In cell and animal models, Khavinson's group showed EDR upregulates AANAT (the rate-limiting enzyme in melatonin synthesis) and TPH1 (tryptophan hydroxylase 1, a serotonin synthesis enzyme). It also shifted the Bcl-2/Bax ratio toward cell survival, increased BDNF expression, and activated PGC-1alpha for mitochondrial biogenesis [1]. A 2017 study confirmed EDR restored neuronal spine density in an in vitro Alzheimer's disease model [2]. A 2024 study tracked EDR reducing oxidative DNA damage in aged induced neurons (DOI 10.3390/ijms25211363).
Community use is niche. Discussion concentrates on Longecity forums (topics 83250 and 111763), not Reddit. Users run 10 to 30 day subcutaneous courses at 100 to 500 mcg per day, typically in the evening. The most consistent report is improved sleep quality and circadian regularity. Cognitive clarity gets mentioned less often and tends to disappoint users expecting something comparable to Semax.
The honest assessment: mechanism is plausible, animal data is consistent, community reports align with the proposed biology. But the entire evidence chain traces back to one group with no independent replication. Treat this as a genuinely experimental compound.
How Pinealon Works
Pinealon (EDR) was originally isolated from Cortexin, a neuroprotective polypeptide drug used in Russian clinical practice. At 418.4 Da, it is small enough to cross the blood-brain barrier and translocate into cell nuclei. Fluorescence-labeled tracking confirmed this nuclear entry [1].
Once inside the nucleus, EDR binds DNA promoter regions and chromatin-associated proteins. The downstream effects mapped so far include upregulation of AANAT, which controls the rate-limiting step of melatonin synthesis. It also increases TPH1 expression, boosting serotonin production upstream of melatonin. This dual pathway modulation explains the circadian rhythm effects users report.
Beyond the melatonin axis, EDR shifts the Bcl-2/Bax apoptosis ratio toward cell survival, reducing programmed cell death in stressed neurons. It activates PGC-1alpha, triggering mitochondrial biogenesis. It increases histone acetylation at neuronal gene loci, loosening chromatin structure to allow transcription of neuroprotective genes. BDNF expression goes up. Antioxidant enzymes SOD2 and GPX1 get upregulated through MAPK/ERK signaling.
The epigenetic mechanism is the key distinction from direct melatonin supplementation. Pinealon does not supply melatonin; it changes the transcriptional environment so the pineal gland produces more of its own. This is why Khavinson protocols specify short courses with long off-periods. The gene expression changes are proposed to persist after the peptide clears, though that claim lacks controlled human confirmation.
Pinealon Benefits
- Pinealon benefits center on circadian rhythm support and neuroprotection, with the strongest signal in sleep-related outcomes.
- Improved sleep onset and circadian rhythm regularity, the most consistently reported benefit across Longecity forums and biohacker community threads. Shift workers describe resynchronization within the first 10 to 14 days of a cycle.
- Neuroprotection via reduced neuronal apoptosis. EDR shifted the Bcl-2/Bax ratio toward cell survival in cortical neuron cultures, and a 2017 study confirmed increased neuronal spine density in Alzheimer's disease cell models [2].
- BDNF upregulation and antioxidant enzyme activation (SOD2, GPX1) through MAPK/ERK pathway modulation. These markers tracked consistently across multiple preclinical papers from the Khavinson group [1].
- Mood stability and stress resilience during weeks 2 through 4 of the cycle, reported by community users on Longecity (topic 111763). Not a stimulant effect; users describe it as background stability rather than a perceptible lift.
- Oral bioavailability. At 418.4 Da, EDR survives gastric digestion better than most peptides. Russian commercial capsules (10 mg, Cytogen brand) exist as a regulated formulation, making Pinealon one of the few injectable peptides with a viable oral alternative.
Pinealon: Science vs Community Consensus
Preclinical-only evidence from a single Russian research group (Khavinson Institute).
Read the evidence (key study, limitations)
EDR translocates to cell nuclei, modulates BDNF, Bcl-2/Bax ratio, AANAT, and TPH1 in animal/cell models. No controlled human clinical trials published.
Khavinson et al., "EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease": Molecules 2021, PMID 33396470. Most recent: Khavinson et al., "Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes": Int J Mol Sci 2024, DOI 10.3390/ijms25211363 (EDR reduced oxidative DNA damage in aged induced neurons; promoted dendritic tree development).
All primary research from a single group with known publication bias. Most papers in Russian or translated without independent replication. No pharmacokinetic studies in humans. No RCTs. Epigenetic claims are mechanistically plausible but unconfirmed.
Niche bioregulator with very low Reddit penetration.
Read the reports (what users report 3, common issues 4)
Users describe subtle effects (sleep quality, circadian restoration, mild cognitive clarity) over 10–20 day cycles. Frequently disappointing for those seeking a measurable nootropic lift.
- Improved sleep onset and circadian rhythm: most consistently reported, especially shift workers
- Subtle cognitive clarity / processing speed increase (non-stimulant quality)
- Mood stability and stress resilience over the 3–4 week cycle
- Effects too subtle: frequently disappoints users seeking a measurable cognitive boost vs. Semax or piracetam
- No observable memory/recall improvement in most users running full cycles
- Single research group + no independent replication creates sourcing and credibility uncertainty
- Confusing mcg (injectable) vs. mg (oral) units creates dosing errors
Science supports circadian/melatonin-pathway modulation via AANAT and TPH1 upregulation. Community sleep and rhythm reports are broadly consistent with that mechanism. Cognitive enhancement claims have weaker scientific backing and limited community verification.
Pinealon Dosage Guide
Start with the math. A 20 mg vial reconstituted with 5 mL bacteriostatic water gives you 4,000 mcg per mL, or 40 mcg per unit on a U100 insulin syringe. So your beginner dose of 100 mcg is 2.5 units. Moderate (200 mcg) is 5 units. Why 5 mL? At 2 mL the same 100 mcg is a single unit, too small to measure accurately. Even 2.5 units is a small draw, so read the syringe carefully. At 200 mcg per day, one vial lasts 100 days, well beyond a single 10 to 30 day course.
Dose in the evening, 1 to 2 hours before sleep. This aligns with the natural melatonin rise and matches the Khavinson protocol.
The most common mistake is confusing mcg (injectable) with mg (oral). A 200 mcg subcutaneous dose is not the same as 200 mg oral. Swapping those units creates a greater than 1,000-fold error. Subcutaneous doses are in micrograms. Oral capsule doses are in milligrams. Double-check your units every time.
Skip caffeine within 6 hours of your evening dose. Store reconstituted vials at 2 to 8 degrees Celsius and use within 3 weeks.
Cycling Protocol
Standard Russian bioregulator cycling protocol. The long off-period is intended to allow endogenous regulatory mechanisms to re-establish. Limited data on optimal cycling.
The Khavinson bioregulator model specifies short course + extended rest based on the epigenetic mechanism: EDR initiates gene transcription changes that persist after the peptide clears (~2–5 min estimated plasma half-life). Continued daily administration beyond 10–30 days is not thought to add incremental benefit once the transcriptional signal is established. The extended off-period (3–6 months) allows the endogenous system to integrate and stabilize changes before the next induction course. The 4-on/8-off weeks structure in peptides.ts approximates this principle but does not precisely match the Khavinson published protocol (10–30 day courses with 3–6 month gaps).
- Effects plateau after week 2–3 of continuous use (suggests transcriptional signal saturation)
- Vivid dreams or mild agitation may indicate diminishing signal-to-noise at extended dosing
- Most Longecity and community users report 2–3 cycles per year, consistent with 3–6 month off recommendations
Or use the universal Peptide Calculator for any peptide.
Pinealon Protocols by Goal
Expected: Improved sleep onset, more consistent circadian rhythm. Community reports effects at 2–3 weeks; repeat cycle after off-period if needed.
Monitor: Monitor for vivid dreams (common); headache (rare). No labs required at this dose.
How to Use Pinealon
- 1Clean the vial stopper with an alcohol swab
Check that your vial has room for 5 mL. Draw 5 mL of bacteriostatic water into a syringe using a mixing needle (18 to 21 gauge). Inject the water slowly down the inside wall of the vial. Do not shake. Swirl gently until the powder dissolves completely. This gives 4,000 mcg per mL (40 mcg per unit on a U100 syringe).
- 2Step 2
Draw your dose into an insulin syringe (29 to 31 gauge, U100). Beginner: 2.5 units (100 mcg). Moderate: 5 units (200 mcg). Aggressive: 5 units (200 mcg) with option to titrate toward 7.5 units (300 mcg) during weeks 3 to 4.
- 3Step 3
Choose an injection site: lower abdomen (1 to 2 inches from the navel), outer thigh, or back of the upper arm. Rotate sites each day.
- 4Step 4
Pinch a small fold of skin, insert the needle at a 45 to 90 degree angle, inject slowly, hold for 5 seconds, then withdraw. Apply light pressure with an alcohol swab if needed.
- 5Timing: inject 1 to 2 hours before sleep
Avoid caffeine within 6 hours of your dose.
- 6Step 6
For oral use: take one 10 mg capsule (or encapsulated lyophilized powder) with a small amount of dietary fat, 1 to 2 hours before sleep. Oral dosing runs 10 to 20 mg per day, reflecting the 20 to 50 times higher dose needed compared to subcutaneous.
- 7Step 7
Store reconstituted vials at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit). Use within 3 weeks. Lyophilized (unreconstituted) vials are stable at room temperature for up to 2 months, or refrigerated for up to 2 years.
Alternative Routes
20–50× higher dose required: 10–20 mg oral vs. 200–500 mcg SC
EDR (~404 Da) survives gastric digestion better than most peptides. Russian Cytogen commercial capsules (10 mg) are the clinical precedent. US research-grade products come as lyophilized powder for encapsulation. Take with a small amount of dietary fat; avoid on an empty stomach. Not reflected in peptides.ts dosingTiers: FLAG P2.
Unknown; no published PK for intranasal EDR
Community reports exist but no dosing data or bioavailability estimates are available. Cannot recommend: dose cannot be established.
Pinealon Stacking Protocols
Works With
Most commonly cited bioregulator combination. Epithalon works upstream (telomere maintenance, AANAT normalization); Pinealon works downstream (direct neuroprotection, serotonin/melatonin synthesis support). No interaction concerns in literature or community.
Run simultaneously during the same 10–20 day course, or sequentially (Epithalon first, then Pinealon after 1–2 weeks).
Khavinson cardiovascular bioregulator layered into longevity stacks alongside Pinealon for multi-system coverage. Referenced in Longecity bioregulator experience thread (topic 83250).
Complementary sleep stack. DSIP for acute insomnia (faster onset); Pinealon for chronic circadian dysregulation (slower, epigenetic mechanism). Not typically combined simultaneously: used for different presentations.
Cognitive enhancement pairing. Semax provides acute BDNF boost and working memory effects; Pinealon provides slower neuroprotective background. Community-reported timing: Semax mornings, Pinealon evenings.
Avoid
Pinealon upregulates TPH1 (tryptophan hydroxylase 1), increasing neuronal serotonin synthesis. Concurrent use with serotonin reuptake inhibitors risks elevated synaptic serotonin. Mechanistically real, not boilerplate.
Do not combineCombined TPH1 upregulation from Pinealon + MAO inhibition blocks serotonin breakdown: serotonin excess risk. Avoid concurrent use.
Do not combineAdditive serotonin precursor load on top of Pinealon TPH1 upregulation. Use with caution or avoid without medical supervision.
Potential additive effects via AANAT pathway modulation. Low physiological doses (0.5 mg) are less concerning; pharmacological doses (5–10 mg) should be avoided during cycle.
Estimated Cost
Pricing updated 2026-04-09
Pinealon Side Effects
The serotonin interaction risk is the most serious safety concern with Pinealon. EDR upregulates TPH1, which increases neuronal serotonin synthesis. Combining Pinealon with SSRIs (fluoxetine, sertraline, escitalopram), SNRIs (venlafaxine), or MAO inhibitors (phenelzine, tranylcypromine, selegiline) could elevate synaptic serotonin to dangerous levels. Serotonin syndrome symptoms include agitation, muscle twitching, diaphoresis, and tachycardia. This is not a theoretical warning on paper. The TPH1 mechanism is documented in preclinical data, and concurrent use with serotonergic medications should be avoided or closely supervised by a physician. 5-HTP supplements add to the same serotonergic load and carry the same caution.
Melatonin supplements at pharmacological doses (3 mg or higher) may produce additive sedation through the AANAT pathway. Low physiological doses around 0.5 mg are less concerning, but stacking 5 to 10 mg melatonin on top of a Pinealon cycle is not advisable.
Vivid dreams are the most commonly reported side effect. They appear in the first 3 to 5 days of a cycle, especially at doses of 200 mcg and above. Most users report normalization by day 7 to 10. This is expected given the melatonin pathway activation and is not a reason to discontinue unless sleep architecture is severely disrupted.
Mild headache occurs rarely. Community reports place this in the first week, resolving without intervention.
Injection-site reactions are standard for subcutaneous administration. Rotate sites. Use a 29 to 31 gauge needle.
The critical limitation: the safety dataset is very small. No controlled human clinical trials have been published. Total published human exposure data across all Khavinson group papers covers a limited number of subjects. No long-term safety monitoring data exists. No pregnancy or breastfeeding safety data exists; avoid use during pregnancy, breastfeeding, and in children or adolescents.
When to stop: if agitation, unusual sleep disruption, or muscle twitching appears during a cycle, discontinue immediately. Check for concurrent serotonergic medications. Wait 3 to 5 days before reassessing. If headache or mood changes persist beyond 3 days, discontinue.
Common Issues & Solutions
No effect after 2 weeks: Pinealon is a slow epigenetic bioregulator: transcriptional changes accumulate over the full course. Expecting stimulant-like onset is the most common mistake. Reassess at 3–4 weeks minimum.
Vivid dreams (common): Expected side effect, especially at 200+ mcg in the first week. Typically normalizes by day 7–10. Not a reason to stop unless sleep architecture is severely disrupted.
Confusing mcg (injectable) with mg (oral): 200 mcg SC ≠ 200 mg oral. A 20 mg vial delivers doses in the microgram range after reconstitution. Oral capsules are in milligrams. Swapping units is a >1,000× error.
Agitation or unusual sleep disruption during cycle: Possible serotonergic load: check for concurrent SSRIs, MAOIs, or 5-HTP. Discontinue Pinealon, wait 3–5 days, reassess.
No benefit after a full cycle: Response rates appear lower in users under 40 without established circadian dysfunction. Primary benefit population is 40+ with age-related sleep/cognitive changes or shift workers.
Ask AI about this page
Ask AI for a second opinion on Pinealon dosing and side effects
Contraindications
- Pregnancy or breastfeeding (no safety data)
- Known hypersensitivity to any component (glutamic acid, aspartic acid, arginine)
- Active autoimmune neurological conditions (theoretical concern: no data)
- Children and adolescents (not studied)
Drug Interactions
- SSRIs and SNRIs (fluoxetine, sertraline, escitalopram): Pinealon upregulates TPH1 (tryptophan hydroxylase 1), increasing neuronal serotonin synthesis. Combining with serotonin reuptake inhibitors could elevate synaptic serotonin; use with medical supervision
- MAO inhibitors (phenelzine, tranylcypromine, selegiline): combined with MAO inhibition, increased serotonin synthesis from Pinealon could contribute to serotonin excess; avoid concurrent use
- Melatonin supplements: potential additive effects on sleep; monitor for excessive sedation
- Sedatives and benzodiazepines: theoretical additive CNS effects
- Immunosuppressants: unknown interaction potential given proposed gene-regulatory activity
- No formal drug interaction studies have been conducted
Product Quality
No USP-grade or pharmaceutical-standard product exists for Western consumers. Russian Cytogen commercial capsules (Khavinson-linked brand) represent the only regulated formulation available. US research-grade products are unregulated; purity varies. EDR is a simple, verifiable tripeptide (HPLC + mass spec confirmation is feasible), which reduces but does not eliminate contamination and mislabeling risk.
- Certificate of analysis (CoA) benchmark: HPLC purity ≥98% and mass spectrometry confirmation of correct molecular weight (418.4 Da for EDR)
- Published third-party batch testing gives an outside check on each lot
- For oral use, Russian Cytogen commercial capsules (10 mg) represent the only standardized form, though availability is limited outside Russia
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Mood / sleep diary (Pittsburgh Sleep Quality Index, PSQI) | Daily during cycle; compare baseline vs. week 2 and end of cycle | Not listed |
| Melatonin levels (serum or first-morning urine) | Optional: baseline before first cycle; repeat at end of cycle if circadian disruption is the primary indication | Not listed |
| Serotonin syndrome symptom check | If co-using any serotonergic drug (SSRI, SNRI, MAOI, 5-HTP) | Clinical assessment: no numeric threshold. Discontinue Pinealon immediately if ≥2 serotonin syndrome criteria met. |
Primary way to gauge response: no biomarker is directly tied to Pinealon activity in humans. PSQI is a validated self-report instrument.
Indirect proxy for AANAT pathway function. Useful in shift workers or confirmed circadian disorder.
TPH1 upregulation adds to serotonergic load. Symptoms: agitation, muscle twitching, diaphoresis, tachycardia.
Pinealon Before and After
Some users report improved sleep onset and subjective sleep quality. These early reports are anecdotal and may reflect placebo response.
Possible improvement in circadian rhythm regularity and morning alertness. Still too early for measurable cognitive effects.
Anecdotal reports of enhanced memory and focus. Neuroprotective effects, if real, would be accumulating at the cellular level but are not directly perceptible. End of standard on-cycle.
Bioregulator theory suggests effects persist after discontinuation as gene expression changes stabilize. This claim lacks controlled human data.
What to Expect
Days 1 through 3: Expect very little. EDR is entering cell nuclei and beginning transcriptional changes at AANAT, TPH1, and antioxidant gene loci. No systemic output is measurable yet. Some users report slightly deeper sleep by night 2 or 3, but most notice nothing. Vivid dreams are common on the first few nights. Mild injection-site discomfort if you are new to subcutaneous injections.
Days 4 through 14: This is the window where circadian effects start showing up. AANAT and TPH1 gene expression changes accumulate. Users who respond describe improved sleep onset and better consistency in their sleep-wake cycle. Morning alertness gets mentioned. Shift workers describe circadian resynchronization here. Vivid dreams usually settle down. Occasional mild headache.
Weeks 2 through 4: Neuroprotective gene expression changes (Bcl-2/Bax, BDNF, SOD2) are accumulating at the cellular level, but there is no direct way to perceive them. A minority of users report subtle cognitive clarity. Mood stability and stress resilience are the more common reports at this stage. Memory improvement is rarely mentioned; if that is your primary goal, expectations should be set realistically.
Post-cycle (weeks 5 through 20 off): Bioregulator theory holds that gene expression changes persist after the peptide clears. This is the core premise of Khavinson cycling, but it has not been confirmed in controlled human trials. Some users report sustained sleep quality and mild cognitive benefit lasting 4 to 6 weeks after stopping. Others notice nothing lasting. Distinguishing real persistence from natural regression to the mean is difficult without formal study design.
Detailed Timeline: Science vs Community
EDR begins translocating to cell nuclei and initiating transcriptional changes at AANAT, TPH1, and antioxidant loci. No measurable systemic output at this stage.
Some users report slightly improved sleep depth by night 2–3. Most report nothing. Placebo-responsive window.
AANAT and TPH1 gene expression changes accumulating. Melatonin synthesis pathway normalization underway in animal models.
Users who respond report improved sleep onset and consistency. Morning alertness noted. Shift workers describe circadian resynchronization in this window.
Neuroprotective gene expression changes (Bcl-2/Bax, BDNF, SOD2) accumulating. No direct perceptible correlate identified in humans.
Subtle cognitive clarity reported by minority of users. Mood stability and stress resilience most cited at this stage. Memory improvement rarely reported.
Bioregulator theory: gene expression changes persist after peptide clearance. Not confirmed in human controlled trials.
Some users report sustained sleep quality and mild cognitive benefit 4–6 weeks post-cycle. Not universal. Difficult to distinguish from natural regression to mean.
Pharmacokinetics
Source: Estimated from tripeptide class pharmacokinetics; no direct PK study for EDR. Small peptides are rapidly cleared (minutes).
Pharmacokinetics: Active Dose Over Time
t½ = ~15-30 minutes (estimated)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is Pinealon Legal?
Pinealon (EDR) is classified as a research chemical in the United States. It is not FDA-approved for any indication. It does not appear on the FDA 503A or 503B bulks lists, so no US compounding pathway exists. It is sold online as a research-grade product, labeled for investigational use only.
In Russia, commercial capsule formulations (Cytogen brand, Khavinson-linked) are available as a regulated product. Availability outside Russia is limited and typically involves importation.
Pinealon has not been evaluated by WADA for athletic competition. Athletes subject to anti-doping testing should verify status with their governing body before use.
No pending FDA regulatory changes have been identified as of October 2026.
This content is for informational and educational purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before using any peptide. Pinealon is an experimental compound with no approved human therapeutic use.
Evidence grade: Small human studies only (Peptide Evidence Gap, October 2026)
Who Should Consider Pinealon
- Adults over 40 experiencing age-related cognitive decline
- Individuals with disrupted sleep-wake cycles or shift workers
- Researchers studying bioregulator peptides and epigenetic gene regulation
- Those interested in neuroprotective strategies (preclinical evidence only)
Related Peptides
What Changed for Pinealon
Peptide Schedule Research TeamReviewed Apr 7, 20266 Citations
References
- [1]EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease (Molecules 2021) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer's Disease (Bull Exp Biol Med 2017) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Pinealon Protects the Rat Offspring from Prenatal Hyperhomocysteinemia (Int J Clin Exp Med 2012) (opens in a new tab)PubMed 22567179PubMed
- Peptides of Pineal Gland and Thymus Prolong Human Life (Neuro Endocrinol Lett 2003) (opens in a new tab)PubMed 14523363PubMed
- Neuroprotective Effects of Peptide Bioregulators in People of Various Age (Adv Gerontol 2013) (opens in a new tab)PubMed 24738258PubMed
- 10.3390/ijms25211363 (DOI: 10.3390/ijms25211363) (opens in a new tab)PubMed
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Pinealon?
Niche. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: Few. Community mentions on Reddit: Very low: no dedicated threads found.
22 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Low search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.